<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424891</url>
  </required_header>
  <id_info>
    <org_study_id>SimEze</org_study_id>
    <nct_id>NCT01424891</nct_id>
  </id_info>
  <brief_title>Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe</brief_title>
  <official_title>Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lowering LDL cholesterol by statins has been proven to be associated with reduction of
      proinflammatory regulators e.g. activation of the transcription factor NF-ĸB. Up to now the
      effects of newer cholesterol lowering agents such as ezetemibe with respect to their
      anti-inflammatory potential are less intensively studied. Therefore the investigators
      analyzed whether equipotent LDL-lowering therapy with simvastatin alone and in combination
      with ezetimibe have comparable effects on NF-ĸB-activation in peripheral blood mononuclear
      cells (PBMCs) of patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NF-kappa B binding activity</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The binding activity of nuclear transcription factor nuclear factor kappa B (NF-kappa B)will be measured in patients with type 2 diabetes before and after 8 weeks while under study treatment. Analysis will be done with electrophoretic mobility shift assay. Nuclear extract, which is necessary, will be generated from peripheral blood mononuclear cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Blood levels of high sensitivity CRP and interleukin-6 will be measured before study start and after 8 weeks while under study medication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo over 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 80 mg of simvastatin over 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sim10/Eze10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 80 mg</intervention_name>
    <description>treatment with 80 mg of simvastatin over a period of 8 weeks</description>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
    <other_name>zocor</other_name>
    <other_name>simvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sim10/Eze10</intervention_name>
    <description>treatment with combination of simvastatin 10 mg and ezetimibe 10 mg</description>
    <arm_group_label>Sim10/Eze10</arm_group_label>
    <other_name>inegy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>treatment with placebo over 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35 to 80 years old

          -  type 2 diabetes

          -  HbA1c value between 6.0 % and 9.0 %

          -  elevated LDL-c values &gt; 100 mg/dl with no lipid lowering treatment within the last six
             month

        Exclusion Criteria:

          -  refused informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gottfried Rudofsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Gottfried Rudofsky</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

